This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| ICD-10 | G71.0 |
| Special Copayment Reduction | V012 · 5 years |
| A. Synonyms | Limb-girdle muscular dystrophy |
| B. Adult onset | Moderate — varies from childhood to adulthood by subtype; recessive forms often begin in childhood to adolescence, dominant forms in adulthood |
| 1. History | In 1954, Walton and Nattrass classified limb-girdle muscular dystrophy separately as distinct from DMD and FSH; gene discoveries in the 1990s began molecular subtype classification; in 2018, the ENMC international consortium proposed the current LGMD-D/R nomenclature |
| 2. Causes | Polygenic: 5 dominant subtypes (LGMD-D), 29 recessive subtypes (LGMD-R); major causative genes include CAPN3, DYSF, SGCA~D, FKRP, ANO5 |
| 3. Genetics | LGMD-D autosomal dominant, LGMD-R autosomal recessive; genes, proteins, and modes of inheritance differ by subtype; NGS panels have greatly improved molecular diagnostic yield |
| 4. Epidemiology | Overall LGMD prevalence 1~2 per 10,000~100,000 (all subtypes combined); in Korea, calpainopathy (LGMD-R1) and dysferlinopathy (LGMD-R2) are relatively common |
| 5. Pathophysiology | Depending on subtype, deficiency or dysfunction of sarcolemmal proteins (sarcoglycans), myofibrillar proteins (calpain-3), membrane repair proteins (dysferlin), glycosylation enzymes (FKRP), etc. causes muscle fiber damage and necrosis |
| 6. Symptoms | Proximal shoulder and pelvic weakness (difficulty climbing stairs, raising arms); subtype suspected by degree of CK elevation; some subtypes accompanied by cardiomyopathy |
| 7. Signs | Winged scapula, waddling gait, Gowers' sign; calf hypertrophy (some subtypes); cardiomyopathy (sarcoglycanopathies, fukutin-related protein deficiency, etc.); serum CK elevated hundreds to thousands of times |
| 8. Screening | Suspect LGMD with proximal weakness + elevated serum CK; predict likely subtype from degree of CK elevation, age, and family history, then NGS panel testing |
| 9. Diagnosis | Serum CK → muscle panel NGS (molecular diagnostic yield 50~80%) → if negative, muscle biopsy (protein expression assessed by immunohistochemistry and Western blot) → integrated clinical-molecular diagnosis |
| 10. Treatment | No FDA-approved disease-modifying treatment; active clinical trials by subtype (LGMD-R1 calpain-3 gene therapy, LGMD-R2 exon skipping, etc.); standard: multidisciplinary supportive care |
| 11. Prognosis | Varies greatly by subtype; calpainopathy and dysferlinopathy progress relatively slowly; some sarcoglycanopathies may lose ambulation in childhood; subtypes with cardiomyopathy carry heart failure risk |
| 12. Prevention | Genetic counseling, prenatal and preimplantation genetic diagnosis; early cardiac monitoring in subtypes with cardiomyopathy; respiratory function surveillance; individualized exercise therapy |
| References | 10 key PMIDs/DOIs |
Limb-Girdle Muscular Dystrophy (LGMD) originated in 1954 when John Walton and Fred Nattrass of the United Kingdom described, as a separate clinical entity, a group of patients with proximal shoulder and pelvic weakness clinically distinct from Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). They classified LGMD as an independent disease on the basis that weakness appears selectively in the pelvic and shoulder girdle (limb-girdle) muscles and that the mode of inheritance is variable.
In the 1990s, with advances in molecular genetics, various gene mutations began to be discovered in LGMD patients. In 1994, mutations in the calpain-3 gene (CAPN3) were identified as the cause of autosomal recessive LGMD (then LGMD 2A), and subsequently in 1995~1997 mutations in the sarcoglycan gene family (SGCA, SGCB, SGCG, SGCD) were found to cause several subtypes. Dysferlin (DYSF) gene mutations were discovered in 1998.
In 2018, the European Neuromuscular Centre (ENMC) international consortium extensively revised the previous LGMD 1A~1H (dominant) and LGMD 2A~2S (recessive) naming system and proposed a new nomenclature reclassifying the dominant forms as LGMD-D (Dominant, D1~D5) and the recessive forms as LGMD-R (Recessive, R1~R29). This system aims to increase clinical accuracy by adding the causative gene name to each subtype. For example, the former LGMD 2A is now written as LGMD-R1 calpain3-related.
LGMD is a heterogeneous group of inherited myopathies in which mutations in more than 30 genes cause proximal shoulder and pelvic weakness. The subtypes established to date number 34 or more in total: 5 dominant (LGMD-D) and 29 recessive (LGMD-R).
Major genes and subtypes: LGMD-R1 (CAPN3, calpain-3 deficiency) — calpainopathy, the most common of the recessive forms, accounting for 12~30% of all LGMD. LGMD-R2 (DYSF, dysferlin deficiency) — dysferlinopathy, overlapping with Miyoshi myopathy. LGMD-R3~R6 (SGCA·SGCB·SGCG·SGCD, sarcoglycan deficiency) — sarcoglycanopathies, DMD-like phenotype possible. LGMD-R9 (FKRP, fukutin-related protein deficiency) — secondary α-dystroglycanopathy, with the severe form overlapping congenital myopathies. LGMD-R12 (ANO5, anoctamin-5 deficiency) — characterized by calf hypertrophy and asymmetric involvement. Dominant forms (LGMD-D): include LGMD-D1 (DNAJB6), LGMD-D2 (TNP03), LGMD-D3 (HNRNPDL), LGMD-D4 (dominant form of CAPN3), and LGMD-D5 (BVES), and tend to have a later age of onset and slower progression.
The degree of serum CK elevation is a clue for suspecting the subtype. In dysferlinopathy (LGMD-R2), CK is markedly elevated tens to hundreds of times, whereas calpainopathy (LGMD-R1) shows moderate elevation. In dominant forms, CK elevation is often mild.
Depending on subtype, LGMD follows autosomal dominant (LGMD-D) or autosomal recessive (LGMD-R) inheritance. Recessive forms are far more numerous and also clinically more common. Patients with recessive forms have mutations in both alleles of the same gene (homozygous or compound heterozygous), and heterozygous carriers are mostly asymptomatic.
Genetic testing strategy: initially, the suspected subtypes are narrowed by integrating the clinical phenotype, CK level, pattern of muscle involvement, age, and racial/ethnic background. Performing a next-generation sequencing (NGS) muscle panel thereafter is the current standard. NGS muscle panels analyze tens to hundreds of myopathy-related genes simultaneously, raising the molecular diagnostic yield to the 50~80% level. If no diagnosis is made by the panel, testing is extended to whole-exome sequencing (WES) or whole-genome sequencing (WGS).
Sarcoglycanopathies (LGMD-R3~R6) show pathology similar to dystrophin-related mechanisms due to deficiency of the sarcoglycan complex, a component of the DAPC, and are clinically similar to DMD, but dystrophin itself is normal. Therefore, normal or secondarily mildly reduced dystrophin antibody staining on muscle biopsy is a diagnostic clue.
The overall prevalence of LGMD is estimated at 1~3 per 100,000 population, but varies greatly by region and ethnicity. The most common recessive form, LGMD-R1 (calpainopathy), shows high frequency in some regions such as Brazil, Spain, and Italy. In the United States, LGMD-R1 is known to account for 12~30% of all LGMD. LGMD-R2 (dysferlinopathy) shows relatively high frequency in the Middle East, North Africa, and Japan.
Situation in Korea: in Korea, the subtype distribution of LGMD has been partly determined through the rare disease registry system and research at neurogenetics centers. In Korea, calpainopathy (LGMD-R1) and dysferlinopathy (LGMD-R2) are reported relatively commonly, and recently increasing reports of ANO5-related LGMD-R12 have also appeared. FKRP-related LGMD-R9 is also not uncommonly diagnosed in Korea.
Sex differences: most LGMD subtypes affect males and females without distinction, but there are reports that males show a more severe phenotype in some recessive forms of dysferlinopathy. The age of onset ranges widely by subtype, from childhood (severe sarcoglycanopathies) to the 40s~50s (dominant forms).
The pathogenic mechanisms of LGMD vary by subtype. They can be broadly classified into four pathological categories.
Deficient sarcolemmal stability: in sarcoglycanopathies (LGMD-R3~R6), the sarcoglycan complex, a component of the DAPC, is deficient, making the sarcolemma unstable, and a DMD-like mechanism of repeated damage–necrosis–fibrosis proceeds. In dysferlinopathy (LGMD-R2), the absence of dysferlin means the repair mechanism of the damaged sarcolemma (membrane repair) does not work, accelerating muscle fiber loss. Dysferlin normally mediates the process by which vesicles within the muscle fiber move to and fuse at the injury site to seal the membrane.
Protease deficiency: calpain-3 (CAPN3) is a calcium-dependent cysteine protease within muscle fibers that is involved in myofibrillar remodeling and regulation of signal transduction. With calpain-3 deficiency in LGMD-R1, impaired muscle remodeling, variation in muscle fiber size, and asymmetric atrophy appear.
Secondary α-dystroglycan glycosylation deficiency: when enzymes such as FKRP, FKTN, and LARGE are deficient, O-glycosylation of α-dystroglycan becomes incomplete, weakening its binding to extracellular matrix components such as laminin and agrin. The spectrum is broad, from the mild form of LGMD-R9 (FKRP-related) to the severe form of congenital muscular dystrophy (CMD).
Abnormal nuclear and RNA processing: the dominant form LGMD-D1 (DNAJB6, DnaJ chaperone-related) involves intranuclear protein aggregation and impaired autophagy, and for LGMD-D3 (HNRNPDL, an RNA-binding protein) and others, abnormal mRNA processing has been proposed as the pathogenic mechanism.
The core symptom of LGMD is weakness of the shoulder girdle (proximal upper limbs) and pelvic girdle (proximal lower limbs). Typically, proximal lower limb weakness appears first, beginning with difficulty climbing stairs, rising from the floor, and running, and later proximal upper limb weakness is added, making it difficult to raise the arms or place objects in high places.
Characteristic symptom patterns by subtype: Calpainopathy (LGMD-R1): onset common in the teens~20s, prominent thigh muscle atrophy without calf hypertrophy, serum CK elevated tens of times or more. Dysferlinopathy (LGMD-R2): onset in the teens~20s, early weakness centered on the gastrocnemius or tibialis anterior, markedly elevated serum CK (hundreds of times). Sarcoglycanopathies (LGMD-R3~R6): onset in childhood~adolescence, rapid DMD-like progression, possible calf pseudohypertrophy, risk of accompanying cardiomyopathy. FKRP-related LGMD-R9: wide range of onset ages from childhood to adulthood, risk of respiratory muscle involvement, calf hypertrophy common.
Systemic involvement: cardiomyopathy is an important complication in sarcoglycanopathies, FKRP-related subtypes, and some dominant forms, and dilated cardiomyopathy or atrial fibrillation may occur. Respiratory muscle weakness progresses in some subtypes such as LGMD-R9 and sarcoglycanopathies and can cause restrictive pulmonary dysfunction and nocturnal hypoventilation. In most LGMD, cognitive function is normal.
On physical examination, winged scapula reflects weakness of the serratus anterior or lower trapezius and is a characteristic sign of LGMD. Gowers' sign (rising from the floor by pushing with the arms) is observed with proximal pelvic weakness. Waddling gait (Trendelenburg gait) is also common. Hypertrophy (true or pseudo) of the calf and triceps muscles is particularly prominent in sarcoglycanopathies and FKRP-related subtypes.
Serum CK: depending on subtype, elevated variably from mild (some dominant forms) to hundreds of times (dysferlinopathy). Very high CK is particularly characteristic of LGMD-R2 (dysferlinopathy). Electromyography shows myopathic changes and spontaneous activity potentials. Muscle MRI is useful in deciding which subtype to suspect first because the pattern of involvement differs by subtype. For example, early involvement of the gastrocnemius is characteristic in dysferlinopathy, while selective fatty replacement of the posterior thigh muscle group appears in calpainopathy.
Cardiac evaluation: echocardiography and electrocardiography are performed from the time of diagnosis and then monitored regularly. In sarcoglycanopathies and FKRP-related subtypes, the incidence of cardiomyopathy is high, so annual echocardiographic follow-up is needed.
Screening for LGMD begins with the combination of proximal weakness and elevated serum CK. When unexplained CK elevation is found in a patient with proximal shoulder or pelvic weakness, an inherited myopathy is suspected and systematic evaluation is begun. A non-episodic, progressive course with a family history increases the likelihood of LGMD.
Predicting subtype by degree of CK elevation: CK elevated hundreds to thousands of times strongly suggests LGMD-R2 (dysferlinopathy) or sarcoglycanopathy. CK elevated tens of times suggests LGMD-R1 (calpainopathy), LGMD-R9 (FKRP-related), etc. Mild CK elevation (10 times or less) suggests a dominant form (LGMD-D) or a case in which considerable time has passed since onset.
Even patients presenting with asymptomatic isolated hyperCKemia may be in a prodromal stage of LGMD, and early diagnosis is possible with muscle MRI and an NGS panel. Family screening: in recessive forms, the parents are heterozygous carriers, so siblings need to be checked for carrier or affected status. In dominant forms, a 50% chance of being affected is considered for parents and children.
The diagnosis of LGMD is made by integrating clinical findings, serum enzyme tests, genetic analysis, and muscle biopsy. Genetic testing currently takes priority, and muscle biopsy plays a complementary role.
Step 1 — Serum CK and basic muscle enzymes: CK, AST, ALT, LDH, aldolase. Step 2 — Muscle MRI: the pattern of muscle involvement provides important clues for narrowing the subtype. T1-weighted images show the pattern of fatty replacement, and STIR images can distinguish acute edema and active inflammation. Step 3 — NGS muscle panel: simultaneous analysis of tens to hundreds of genes. Molecular diagnostic yield 50~80%. Once the diagnosis is established, management is possible without muscle biopsy. Step 4 — Muscle biopsy (if needed): basic histochemistry such as H&E, Gomori trichrome, ATPase. Immunohistochemistry (IHC): antibody panel for calpain-3, dysferlin, sarcoglycans (α·β·γ·δ), dystrophin, α-dystroglycan. Quantification of protein expression by Western blot. Step 5 — Functional assessment: evaluation of multi-organ involvement by echocardiography, electrocardiography, and pulmonary function tests (FVC, FEV1).
Differential diagnosis: polymyositis (inflammatory myopathy) is distinguished by acute serum CK elevation, myalgia, and positive immune markers. Metabolic myopathy (acidosis) is suspected from exercise-induced myalgia and fluctuating CK. Adult-type spinal muscular atrophy (SMA) is distinguished by the anterior horn cell lesion pattern and electromyography.
There is currently no FDA- or EMA-approved disease-modifying treatment for any LGMD subtype. Multidisciplinary supportive care is the standard treatment, and subtype-specific clinical trials are actively under way.
Supportive care: physical therapy (maintaining strength, flexibility training, preventing joint contractures), occupational therapy, assistive devices (AFO, wheelchair, walking aids), respiratory rehabilitation (mechanical ventilation, cough assist device), cardiac treatment (ACE inhibitors and beta-blockers; subtypes with cardiomyopathy), speech therapy (when dysphagia develops), psychosocial support.
Treatments under investigation: LGMD-R1 (calpainopathy): AAV-based CAPN3 gene therapy in phase 1/2 clinical trials. LGMD-R2 (dysferlinopathy): exon skipping and hydrolase replacement strategies under study. LGMD-R3~R6 (sarcoglycanopathies): active preclinical gene therapy research. LGMD-R9 (FKRP-related): exon skipping and gene therapy in both preclinical and clinical studies. In some subtypes, adjunctive therapies such as riboflavin, antioxidants, and creatine monohydrate have been studied, but the evidence is limited.
Exercise prescription: excessive high-intensity exercise can worsen muscle damage, so moderate aerobic exercise and light resistance exercise are recommended. Aquatic exercise places little load on the joints and is an effective alternative.
The prognosis of LGMD varies greatly by subtype. In general, recessive forms show earlier onset and faster progression than dominant forms. Sarcoglycanopathies (LGMD-R3~R6): childhood onset, with a wide range from severe phenotypes that may lose ambulation in the teens to mild forms in which ambulation can be maintained into adulthood. Cardiomyopathy and respiratory failure can be major causes of death. Calpainopathy (LGMD-R1): relatively slow progression; ambulation is often lost 20~30 years after onset, and some maintain independent ambulation into their 60s. Cardiomyopathy is rare.
Dysferlinopathy (LGMD-R2): early CK is very high and muscle damage is severe, but the rate of progression varies. Accompanying cardiomyopathy is rare. FKRP-related (LGMD-R9): the mild form (LGMD) shows relatively slow progression after adult onset, but attention must be paid to respiratory muscle involvement. Dominant forms (LGMD-D): adult onset, generally slow progression, and most maintain ambulatory function for a long time. Overall, early diagnosis, active cardiopulmonary management, and rehabilitation are important for improving prognosis.
LGMD is an inherited myopathy, and fundamental prevention is achieved through genetic counseling and prenatal and preimplantation genetic diagnosis. Recessive forms (LGMD-R): when both parents are heterozygous carriers, each child has a 25% risk of being affected, so carrier genetic testing is offered after confirming the family history. Implantation of affected embryos can be prevented through PGT-M. Dominant forms (LGMD-D): 50% risk for children of an affected parent; prenatal and preimplantation diagnosis approached in the same way.
Secondary prevention: in subtypes with cardiomyopathy (sarcoglycanopathies, FKRP-related), echocardiography is performed regularly from early on (at diagnosis, then every 1~2 years), and prophylactic ACE inhibitor administration is considered before the left ventricular ejection fraction declines. In subtypes in which respiratory muscle weakness is expected, FVC is measured every 6 months, and nocturnal BiPAP is introduced when FVC is 50% or less or symptoms of nocturnal hypoventilation appear. Regular stretching and passive and active range-of-motion exercises are performed to prevent joint contractures.